Literature DB >> 17654559

Comparative efficacy of repetitive nerve stimulation, exercise, and cold in differentiating myotonic disorders.

Patrik Michel1, Damien Sternberg, Pierre-Yves Jeannet, Murielle Dunand, Francine Thonney, Wolfram Kress, Bertrand Fontaine, Emmanuel Fournier, Thierry Kuntzer.   

Abstract

The decremental response of the compound muscle action potential (CMAP) to provocative tests is not characterized in genetically verified myotonic disorders. We therefore studied the relationship between decremental responses and mutation type in 10 patients with recessive myotonia congenita (rMC), two with paramyotonia congenita (PMC), nine with myotonic dystrophy type 1 (DM1), four with DM2, and 14 healthy people. CMAPs were measured at rest, just after a short exercise test (SET), and during short, 5- and 10-HZ, repetitive nerve stimulation (RNS) trains at 32 degrees C and at 20 degrees C. The degree of decrement was not related to the severity of clinical myotonia. Controls and PMC patients had similar responses when warm, but with cooling PMC patients had a persistent decrement of CMAPs. In the rMC patients the decremental responses were related to the type of mutation of the CLCN1 gene, as a decrement was encountered in the T268M, R894X, IVS17+1 G>T, K248X, and 2149 del G, but not with the IVS1+3 A>T, F167L, or dominant A313T mutations. In DM1 patients there was no relationship between decrement and CTG repeats. The degree of partial inexcitability in myotonic muscle membrane therefore depends on the mutation type rather than degree of clinical myotonia. RNS at 10 HZ is more sensitive than SET for demonstrating abnormalities in rMC patients when warm; differences are less marked when cold, which is useful to diagnose PMC. Provocative tests are therefore useful in myotonias to demonstrate muscle inexcitability, which depends on the chloride or sodium channelopathy.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17654559     DOI: 10.1002/mus.20856

Source DB:  PubMed          Journal:  Muscle Nerve        ISSN: 0148-639X            Impact factor:   3.217


  9 in total

1.  Refined exercise testing can aid DNA-based diagnosis in muscle channelopathies.

Authors:  S Veronica Tan; Emma Matthews; Melissa Barber; James A Burge; Sanjeev Rajakulendran; Doreen Fialho; Richa Sud; Andrea Haworth; Martin Koltzenburg; Michael G Hanna
Journal:  Ann Neurol       Date:  2011-02       Impact factor: 10.422

2.  Coexistence of CLCN1 and SCN4A mutations in one family suffering from myotonia.

Authors:  Lorenzo Maggi; Sabrina Ravaglia; Alessandro Farinato; Raffaella Brugnoni; Concetta Altamura; Paola Imbrici; Diana Conte Camerino; Alessandro Padovani; Renato Mantegazza; Pia Bernasconi; Jean-François Desaphy; Massimiliano Filosto
Journal:  Neurogenetics       Date:  2017-10-09       Impact factor: 2.660

Review 3.  The non-dystrophic myotonias: molecular pathogenesis, diagnosis and treatment.

Authors:  E Matthews; D Fialho; S V Tan; S L Venance; S C Cannon; D Sternberg; B Fontaine; A A Amato; R J Barohn; R C Griggs; M G Hanna
Journal:  Brain       Date:  2009-11-16       Impact factor: 13.501

4.  Voltage-gated sodium channels: biophysics, pharmacology, and related channelopathies.

Authors:  Eleonora Savio-Galimberti; Michael H Gollob; Dawood Darbar
Journal:  Front Pharmacol       Date:  2012-07-11       Impact factor: 5.810

5.  A novel mutation in CLCN1 associated with feline myotonia congenita.

Authors:  Barbara Gandolfi; Rob J Daniel; Dennis P O'Brien; Ling T Guo; Melanie D Youngs; Stacey B Leach; Boyd R Jones; G Diane Shelton; Leslie A Lyons
Journal:  PLoS One       Date:  2014-10-30       Impact factor: 3.240

6.  Predominantly myalgic phenotype caused by the c.3466G>A p.A1156T mutation in SCN4A gene.

Authors:  Johanna Palmio; Satu Sandell; Michael G Hanna; Roope Männikkö; Sini Penttilä; Bjarne Udd
Journal:  Neurology       Date:  2017-03-22       Impact factor: 9.910

7.  Novel CLCN1 mutations and clinical features of Korean patients with myotonia congenita.

Authors:  In-Soo Moon; Hyang-Sook Kim; Jin-Hong Shin; Yeong-Eun Park; Kyu-Hyun Park; Yong-Bum Shin; Jong Seok Bae; Young-Chul Choi; Dae-Seong Kim
Journal:  J Korean Med Sci       Date:  2009-11-09       Impact factor: 2.153

8.  Functional characterization of ClC-1 mutations from patients affected by recessive myotonia congenita presenting with different clinical phenotypes.

Authors:  Jean-François Desaphy; Gianluca Gramegna; Concetta Altamura; Maria Maddalena Dinardo; Paola Imbrici; Alfred L George; Anna Modoni; Mauro Lomonaco; Diana Conte Camerino
Journal:  Exp Neurol       Date:  2013-08-08       Impact factor: 5.330

9.  Study protocol for the MEXiletine hydrochloride administration trial: a placebo-controlled, randomised, double-blind, multicentre, crossover study of its efficacy and safety in spinal and bulbar muscular atrophy (MEXPRESS).

Authors:  Shinichiro Yamada; Atsushi Hashizume; Yasuhiro Hijikata; Tomonori Inagaki; Daisuke Ito; Fumie Kinoshita; Masahiro Nakatochi; Yumiko Kobayashi; Akihiro Hirakawa; Tomohiko Nakamura; Masahisa Katsuno
Journal:  BMJ Open       Date:  2018-09-11       Impact factor: 2.692

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.